Wolverine Stack (20 mg)

Sponsored

At a Glance

The Wolverine Stack is a pre-mixed 20 mg vial containing BPC-157 (10 mg) + TB-500 (10 mg) in a 1:1 ratio — the most widely used research peptide combination for musculoskeletal recovery. BPC-157 drives local repair; TB-500 provides systemic healing support. Together they address all three phases of tissue healing.[1][2]

• Reconstitute: Add 3.0 mL bacteriostatic water → 6.67 mg/mL total blend (3.33 mg/mL each component).
• Standard dose: Titrate once daily from 500 mcg (Weeks 1–2) → 666 mcg (Weeks 3–4) → 1,000 mcg (Weeks 5–8).
• Easy measuring: At 6.67 mg/mL on a U-100 syringe, 1 unit = 0.01 mL ≈ 66.7 mcg total blend.
• Storage: Lyophilised: freeze at −20 °C; reconstituted: refrigerate at 2–8 °C; use within 4 weeks.

Overview

• Composition: BPC-157 10 mg + TB-500 10 mg (1:1 ratio) in a pre-mixed 20 mg lyophilised vial.
• Goal: Comprehensive musculoskeletal tissue repair combining BPC-157's local healing with TB-500's systemic reach.[1][2]
• Schedule: Once-daily SC injection throughout a 4–8 week course, with the daily dose titrated upward over the cycle.
• Reconstitution: 3.0 mL BAC water per 20 mg vial → 6.67 mg/mL.
• Storage: Lyophilised at −20 °C; reconstituted at 2–8 °C; use within 4 weeks.

What You’ll Need

Plan based on a full 8-week once-daily titrated cycle (56 injections, ~44.3 mg total blend consumed).

• Wolverine Stack Vials (20 mg each): Weeks 1–2 (500 mcg × 14 = 7 mg) + Weeks 3–4 (666 mcg × 14 ≈ 9.3 mg) + Weeks 5–8 (1,000 mcg × 28 = 28 mg) ≈ 44.3 mg ÷ 20 mg per vial → 3 vials cover the full 8-week cycle.
• Insulin Syringes (U-100, 0.3 mL / 30-unit preferred): 56 injections → 56 syringes.
• Bacteriostatic Water (10 mL bottles): 3.0 mL per vial × 3 vials = 9 mL → 1 × 10 mL bottle.
• Alcohol Swabs: 2 per injection → 112 swabs per 8-week cycle.

How to Reconstitute

1. Allow frozen lyophilised vial to reach room temperature (10–15 minutes).
2. Draw 3.0 mL bacteriostatic water with a sterile syringe.
3. Inject slowly down the inner vial wall; avoid injecting directly onto the powder cake.
4. Gently swirl until fully dissolved — do not shake. Solution should be clear and colourless.
5. Label with reconstitution date and both peptide names; refrigerate at 2–8 °C, protected from light. Use within 4 weeks.

Dosing Schedule

Start at 500 mcg once daily (7.5 units / 0.075 mL) for the first two weeks to assess tolerance, then step up to 666 mcg (10 units / 0.10 mL) in weeks 3–4 and 1,000 mcg (15 units / 0.15 mL) from week 5 onward. Each dose splits roughly 1:1 between BPC-157 and TB-500. Run a 4–8 week course; if recovery goals warrant a second course, take a 6-week break before cycling again.

Protocol Details

• Weeks 1–2: 500 mcg (7.5 units / 0.075 mL) once daily SC → ~250 mcg BPC-157 + ~250 mcg TB-500.[1]
• Weeks 3–4: 666 mcg (10 units / 0.10 mL) once daily SC → ~333 mcg BPC-157 + ~333 mcg TB-500.
• Weeks 5–8: 1,000 mcg (15 units / 0.15 mL) once daily SC → ~500 mcg BPC-157 + ~500 mcg TB-500.
• Injection site: Near injury site for BPC-157's local effect; abdomen or thigh adequate for TB-500's systemic distribution.
• Duration: Run a 4–8 week course; for a repeat course, allow a 6-week break before cycling again.

Storage

• Lyophilised: Store at −20 °C (−4 °F); protect from moisture and light.
• Reconstituted: Refrigerate at 2–8 °C. Do not freeze. Use within 4 weeks.
• Appearance: Clear, colourless solution. Discard if cloudy or particulate.

How the Wolverine Stack Works

BPC-157 and TB-500 address tissue healing through complementary, non-overlapping mechanisms that together cover all three phases of tissue repair:

• Phase 1 — Inflammatory (Days 1–5): TB-500 down-regulates NF-κB and pro-inflammatory cytokines (IL-6, TNF-α); BPC-157 normalises the NO pathway and reduces prostaglandin E2 — together shortening the inflammatory phase.[2]
• Phase 2 — Proliferative (Days 5–21): BPC-157 activates FAK-paxillin in tendon fibroblasts and endothelial cells; TB-500 enables cell migration via G-actin sequestration. Both drive angiogenesis to restore blood supply to the injured site.[1]
• Phase 3 — Remodelling (Weeks 3+): TB-500 reduces myofibroblast persistence, limiting fibrosis; BPC-157 supports collagen organisation and tendon cell maturation for restoration of mechanical strength.

Good to Know

• The pre-mixed vial ensures consistent 1:1 dosing of both components — no need for individual reconstitution and mixing.
• For acute localised injuries, inject subcutaneously within 2–5 cm of the injury site to maximise BPC-157's local FAK-paxillin effects.
• WADA-prohibited — both BPC-157 and TB-500 are classified as non-approved peptide hormones (Category S2). Athletes subject to anti-doping rules must not use this stack.
• Track pain scores (NRS scale), range of motion, and swelling at weeks 2, 4, and 8.
• The Wolverine Stack can be upgraded to the GLOW or KLOW blend for broader tissue repair and skin/immune support. See KLOW Protocol.
• Musculoskeletal repair: BPC-157 orthopaedic review: 35 preclinical studies + 1 human pilot showing benefit in tendon, muscle, bone, and cartilage repair.[1]
• Systemic reach: TB-500 distributes body-wide after SC injection, supporting healing in multiple tissues simultaneously.[2]
• Gut protection: BPC-157 component provides additional gut mucosal protection — useful for athletes using NSAIDs during recovery.
• Complementary mechanisms: Local (BPC-157) + systemic (TB-500) repair is more comprehensive than either peptide alone.
• WADA status: Both components prohibited in- and out-of-competition. Not suitable for tested athletes.
• For background on the Wolverine Stack's mechanism, evidence, and safety profile, see What Is the Wolverine Stack?.

Tips for Best Results

• Maintain adequate dietary protein (1.2–1.6 g/kg body weight) for tissue synthesis.
• Gentle range-of-motion exercises within pain-free range support capillary ingrowth and fibroblast recruitment.
• Avoid NSAIDs — they blunt prostaglandin-mediated repair signalling that BPC-157 potentiates.
• Adequate sleep (7–9 hours) maximises overnight tissue repair processes.

Injection Tips

• Clean the vial stopper and injection site with separate alcohol swabs; allow both to air-dry fully before proceeding.
• Using a 29–31 gauge insulin syringe (5/16″ to 1/2″ needle), draw the calculated dose precisely.
• Pinch a fold of skin and insert the needle at 45° into subcutaneous fat (90° is acceptable with a short needle into a well-pinched fold).
• Inject slowly over 2–3 seconds; do not aspirate. Withdraw the needle, apply gentle pressure, and do not rub the site.
• Rotate injection sites (abdomen, thighs, upper arms) and dispose of each syringe in a sharps container immediately after use.